Skip to content
MARKETS / NYSE / HIMS
NYSE · SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE · LARGE CAP

Hims & Hers Health, Inc. HIMS

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.3B
▲ 59.0% YoY
$128.4M
▲ 1.8% YoY
$57.4M
▼ 71.0% YoY
In brief

What this company does

Hims & Hers Health, Inc. connects patients to licensed healthcare professionals who can prescribe medications when appropriate, with prescriptions fulfilled online through licensed pharmacies. It also offers access to a range of non-prescription health and wellness products. Its digital platform enables access to treatments for a broad range of chronic conditions, including those related to sexual health, hair loss, hormone health, weight loss, dermatology and mental health, as well as services such as comprehensive laboratory testing. Its facilities include a licensed 503B compounding outsourcing facility, a peptide manufacturing facility and a laboratory testing services facility. Since its founding, the company has facilitated over fifty million telehealth consultations for people in the United States, Canada, the United Kingdom and the European Union, including Germany, the Republic of Ireland, France and Spain. As of December 31, 2025, its team was comprised of 2,442 employees across various functions. Hims & Hers Health, Inc. launched in 2017.

Written from the business description in Hims & Hers Health, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 23 February 2026. Every sentence was checked against that document before publication.

Growth
USD 2.3B
Revenue, FY2025 · full 7-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.3 · Net income 0.1
0.8B1.6B2019202020212022202320242025
Compound annual growth
+64.5%
+73.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +73.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
5 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 4.5% · Net 5.5%
-50%2019202020212022202320242025
ROE
FY2025 · ROE 25.2%
10%20%30%-50%-100%2019202020212022202320242025

Each USD of equity produced 25 cents of profit this year.

Cash & shareholders
USD 78.9M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 57.4
80M160M-20M2019202020212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 78.9
40M2019202020212022202320242025

USD 78.9M in buybacks — 61% of the year's profit went back to shareholders.

Total assetsUSD 2.2B
EquityUSD 540.9M
CashUSD 228.6M
Current ratio1.90×

Equity funds 25% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B2.31.50.90.50.30.10.1
Operating income $B0.10.1−0.0−0.1−0.1−0.0−0.1
EBITDA $B0.20.1−0.0−0.1−0.1−0.0−0.1
Income tax $B−0.0−0.10.0−0.0−0.00.00.0
Net income $B0.10.1−0.0−0.1−0.1−0.0−0.1
Free cash flow $B0.10.20.0−0.0···
EPS, diluted $0.510.53−0.11−0.32−0.58−0.51−2.07
Dividend / sh $·······
Payout %·······
ROE %25.230.7−7.2−20.3−114.7··

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 35 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 60 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Offices & Clinics of Doctors of Medicine
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image